The ALS Network and ALS United are inviting U.S. researchers to submit proposals for a new round of funding aimed at accelerating progress toward new treatments for amyotrophic lateral sclerosis (ALS). The funding is part of the expanding ALS Research Innovation Initiative. It’s intended to support “bold” and …

Several commonly used medications may be repurposed to extend survival in people with amyotrophic lateral sclerosis (ALS), according to an analysis of the electronic medical records of more than 11,000 U.S. veterans. Researchers found that certain classes of medications were associated with improved survival in ALS, including statins, which…

An analysis of how polarized light interacts with clumps of proteins in the eyes may help differentiate amyotrophic lateral sclerosis (ALS) from Alzheimer’s disease and related conditions, a new study shows. In experiments using post-mortem retinal samples — a light-sensitive layer at the back of the eye — researchers…

A Phase 2 clinical trial showed that early treatment with the experimental oral therapy PrimeC slowed functional decline and reduced the risk of death or ALS complications for people with amyotrophic lateral sclerosis (ALS) compared with a six-month delay in treatment. Top-line results from the main Phase 2…

A brain implant to detect attempted finger movements can enable people paralyzed by conditions such as amyotrophic lateral sclerosis (ALS) to type on a computer, a study showed. The findings build on a rapidly growing field of research into so-called implantable brain-computer interfaces (iBCIs), in which electrodes are implanted…

Acurastem has received a research grant from Target ALS to develop potential therapies for amyotrophic lateral sclerosis (ALS) that target SYF2, a protein involved in regulating TDP-43 function. Abnormalities in the TDP-43 protein are a hallmark of ALS and are believed to play a central role in…

Amydis has received a $2.5 million grant from the National Institutes of Health (NIH) to develop a simple eye test that could help detect toxic deposits of the TDP-43 protein — a hallmark of amyotrophic lateral sclerosis (ALS) and several other neurodegenerative diseases. With the funding from the…

Keros Therapeutics is collaborating with Massachusetts General Hospital to design a clinical trial evaluating its therapy candidate rinvatercept in people with amyotrophic lateral sclerosis (ALS). According to the developer, the therapy may help preserve muscle strength and function, and improve quality of life, for those with the progressive…

People with amyotrophic lateral sclerosis (ALS) who were exposed to smoke from wildfires prior to developing the disease are more than twice as likely to experience respiratory failure or death, according to a new analysis. The findings underscore the need for further research to understand how air pollution and…

The ALS Network will continue to host its ASK ME webinar series throughout 2026, featuring expert-led sessions on advocacy, care, research, and daily life with amyotrophic lateral sclerosis (ALS). This…